Dorian Haci on MintNeuro's modular chip strategy and the standardization of neurotech hardware
Summary
Dorian Haci, CEO of MintNeuro, argues that neurotech is suffering from a hardware bottleneck due to a lack of standardization, with researchers constantly reinventing chips. He positions MintNeuro as a provider of modular, mixed-signal chips that act as foundational 'Lego bricks' for medical device companies, similar to the ARM model in semiconductors. Haci compares the current neurotech landscape to the AI industry ten years prior, predicting significant growth and consolidation as foundational layers mature. He emphasizes that long-term success requires navigating regulatory approval and reimbursement, not just technical innovation. The company has raised $5 million and aims to scale globally, leveraging a team with deep expertise in semiconductors, medical devices, and neuroscience.
Key takeaways
- 1 MintNeuro designs modular, function-specific chips (sensing, stimulation, safety) rather than ASICs, allowing partners to combine them for different conditions like epilepsy or Parkinson's.
Dorian Haci · 10:51
- 2 I believe that Near Tech and BCI is where AI was 10 years ago.
Dorian Haci · 22:32
- 3 Long-term commercial viability in implantable neurotech depends on navigating the 'reimbursement mountain,' requiring proof of economic feasibility within healthcare economics.
Dorian Haci · 19:54
Episode sections
- 1:33 – 2:56
Introduction and Dorian Haci's Background
Dorian Haci introduces himself as the CEO and co-founder of MintNeuro, detailing his academic journey from Italy to Imperial College London and the founding of the company with his former supervisor.
- 2:56 – 6:17
Motivation for Neurotech and Spinning Out of Academia
Haci explains his focus on the brain stems from a desire to create real-world impact for patients, noting that the decision to leave academia was driven by the hardware bottleneck and lack of standardization.
- 6:17 – 12:25
MintNeuro's Chip Architecture and Modular Approach
Haci distinguishes MintNeuro's mixed-signal circuits from general-purpose CPUs/GPUs, describing a strategy of building modular, function-specific chips ('Lego bricks') rather than ASICs.
- 12:25 – 16:16
Business Model and Customer Partnerships
Haci outlines how MintNeuro positions itself as a partner to medical device companies, helping them navigate the difficulties of using off-the-shelf components or building in-house semiconductor teams.
- 16:16 – 22:05
BCI Landscape and Neurotech Categories
Haci categorizes neurotech into five areas and notes that while BCI attracts hype, long-term success requires demonstrating medical impact and economic feasibility through regulatory approval.
- 22:05 – 27:31
Supply Chain Dynamics and Industry Growth
Haci compares the current neurotech state to AI ten years prior, predicting a segmented supply chain where foundational layers like chips become standardized.
- 27:31 – 30:58
Investment Drivers and Future Outlook
Haci attributes capital influx to fascination with the brain and AI safety narratives, predicting a 'ChatGPT moment' for neurotech where devices become commoditized.
- 30:58 – 32:32
Funding History and Recent Round
Haci details MintNeuro's funding path, including grants and a recent $5 million close, aiming to build a syndicate of investors who understand both hardware and medical applications.
- 32:32 – 33:29
Investor Support and Scaling Strategy
Haci identifies lead investor Odyssey Ventures as a key partner for international scaling, emphasizing value beyond capital.
- 33:29 – 34:29
Fundraising and Resource Efficiency
Adam Fraser and Dorian Haci discuss the $5 million raise, with Haci describing the company's 'resourceful' growth to nearly 30 employees.
- 34:29 – 34:49
NVIDIA Comparison and Growth Model
Haci compares MintNeuro's approach to NVIDIA's long-term growth, noting it took 9 years for NVIDIA to reach $1 billion in revenue.
- 34:49 – 36:20
Global Ambitions and US Presence
Haci states MintNeuro aims to be a global company, with the CEO based in San Francisco to support US and Asian market expansion.
- 36:20 – 37:58
Founder Team Expertise and Transition
Haci explains his transition from academia to commercial leadership, highlighting the deep domain expertise of his co-founders in semiconductors, medical devices, and neuroscience.
- 37:58 – 40:16
Business Training and Commercial Adaptation
Haci details his business training through programs like MatEx Superconnector and Chipstart UK, noting his role is to understand limitations and manage specialists.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| NVIDIANVDA | equity | neutral | with the AI revolution, everyone's suddenly an expert on NVIDIA and the difference between a GPU and a CPU, but we hear terms semiconductor. semiconductors, silicon, chips, processors, GPUs. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
MintNeuro recently closed around $5 million in funding to move from lab to commercial supply.
Adam Fraser ·0:36
How to verify: Check MintNeuro's press releases or SEC filings (if public) or news archives for funding announcements around late 2026/2026. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Primary sourceDorian Haci studied at Imperial College London in the Next Generation Neural Interfaces team.
Dorian Haci ·2:12
How to verify: Check academic publications or LinkedIn profiles of Dorian Haci and the Next Generation Neural Interfaces team members. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
The team designed over 40 chips in the past 15 years specifically in NeuroTech.
Dorian Haci ·4:38
How to verify: Review academic patents or publications from the Imperial College team between 2026 and 2026. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
MintNeuro works with Motif, a US company treating severe depression.
Dorian Haci ·5:18
How to verify: Check Motif Neurotech's press releases or partnership announcements for collaborations with MintNeuro. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
There are primarily three ways to get chips: off-the-shelf, design houses, or in-house teams.
Dorian Haci ·12:45
How to verify: Industry analysis reports on semiconductor supply chains for medical devices. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
MintNeuro raised £1 million about two years ago and $5 million a month ago.
Dorian Haci ·31:52
How to verify: Check MintNeuro's press releases or news archives for funding announcements in late 2026 and late 2026. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
MintNeuro received funding from NIHR, Innovate UK, and ARIA.
Dorian Haci ·31:32
How to verify: Check grant award databases from NIHR, Innovate UK, and ARIA for awards to MintNeuro or its founders. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Odyssey Ventures is an AI and deep tech investor based in London with offices in San Francisco and New York.
Dorian Haci ·32:52
How to verify: Check Odyssey Ventures website or LinkedIn page for office locations and investment thesis. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
MintNeuro raised $5 million.
Adam Fraser ·33:29
How to verify: Check MintNeuro press releases, Crunchbase, or PitchBook for funding rounds. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
NVIDIA was founded in 1993.
Unidentified speaker (speaker_2) ·34:29
How to verify: Check NVIDIA investor relations page or Wikipedia for founding date. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Primary sourceNVIDIA crossed $1 billion in revenue in 2002.
Dorian Haci ·35:28
How to verify: Check NVIDIA annual reports (10-K) filed with SEC EDGAR for fiscal year 2002 revenue. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Primary sourceTim Denison has over 15 years of experience at Medtronic.
Unidentified speaker (UNKNOWN) ·36:49
How to verify: Check Tim Denison's LinkedIn profile or Medtronic press releases mentioning his tenure. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Dorian Haci has 12 years of experience in the industry.
Unidentified speaker (speaker_2) ·36:43
How to verify: Check Dorian Haci's LinkedIn profile or bio for years of experience. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Dorian Haci was an Enterprise Fellow of the Royal Academy of Engineering.
Dorian Haci ·37:58
How to verify: Check Royal Academy of Engineering website or Dorian Haci's LinkedIn profile for fellowship details. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
MintNeuro's website is Mintneuro.com.
Dorian Haci ·39:32
How to verify: Visit Mintneuro.com to verify domain ownership and content. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
The podcast is called The Business Of Neurotech and the website is businessofneurotech.com.
Adam Fraser ·39:53
How to verify: Visit businessofneurotech.com to verify podcast details. For recent events, verify 2026-08-16 through 2026-11-16. Use another period only when the speaker explicitly names it.
Do your own research
- Verify MintNeuro's current product portfolio and any FDA/CE clearance status for their chips via the company website and regulatory databases.
- Check the financials and portfolio of lead investor Odyssey Ventures to assess their commitment to deep tech scaling.
- Review the regulatory pathway for 'mixed-signal' implantable devices to understand the 'reimbursement mountain' challenges cited.
- Analyze the competitive landscape of neurotech chips, specifically looking for other modular or standardized chip providers beyond MintNeuro.
- Confirm the employment status and tenure of key founders (Denison, Cosandino, Jackson) at previous companies like Medtronic to validate claimed expertise.
- Search for clinical trial data or published research from MintNeuro's academic origins at Imperial College London to assess the maturity of their technology.
- Evaluate the total addressable market for implantable neurotech devices versus the hype surrounding BCI for enhancement.
- Check for any conflicts of interest or prior affiliations between the speakers and competitors in the neurotech space.
Full transcriptexpand
- 0:01
- Unidentified speaker (UNKNOWN): From
- 0:01
- Adam Fraser: breakthrough devices to the bottom line, we explore the investment trends, the commercial models, and the strategic thinking required to bring neurotechnology to the global market. This is the business of Neurotech.
- 0:16
- Adam Fraser: Hello, everybody, and welcome to the show. I'm your host, Adam Fraser, and today I'm delighted to be joined by Dr. Dorian Harchy, Hachi, co-founder and CEO of Mint Neuro. Every neural device depends on the chips inside it, and Mint Neuro, which spun out of the Imperial College London, designs low-power chips that sense and stimulate the
- 0:36
- Adam Fraser: nervous system. So companies can build smaller implants for conditions like depression, epilepsy, and Parkinson's. It's recently close around $5 million to take its chips from the lab very much into the commercial supply. Dorian, very big welcome to the Business of Neurotech Podcast.
- 0:51
- Unidentified speaker (UNKNOWN): Hi,
- 0:51
- Dorian Haci: Adam. Thank you for having me. I'm a big fan of the podcast, so it's a pleasure.
- 0:56
- Adam Fraser: Very kind of you to say so. Thank you, Dorian. Look, it's very good timing. I'm I think as of publishing today, 16 episodes in. I've been lucky enough to have three BCI founders on from Neurosoft, from Paradromics, from Axoft. Agsoft. I don't want to make this all about BCI, but a lot of focus in the Neurotech sector. on BCI. You're very much
- 1:16
- Adam Fraser: the kind of picks and shovel seller into that sector. So very much looking to exploring your business model and the science behind what you're doing. But look, please, we'll get into Mint Euro, but maybe just kick things off, introduce yourself to the audience, tell us a bit about your backstory up to the point where you founded Mint Neuro.
- 1:33
- Dorian Haci: I'm Dorian, I'm the CEO and co-founder co founder of Mint Neuro. I'm an electronic engineer by background. but I think my my interest for electronics goes back to when I was a kid when I was tearing apart radios and video recorders at home, then trying to put them together was another story. But I always had the passion for electronics. And then when I grew up, I studied
- 1:53
- Dorian Haci: electrical electronic engineering, but I had also the fascination with the brain and the nervous system and neuroscience in general. And during my masters, I studied started in Italy, by the way, and in Italy the master's. is two years. The second year, I had the possibility to travel abroad, and I managed to join the Imperial College London, and I joined a research team called the Next Generation Neural
- 2:12
- Dorian Haci: Interfaces, which was exactly the intersection of those two passions of mine. And so since then, then I became a researcher within the team and I did also a PhD at the same time. And I graduated and did a the postdoc, and my co-founder, Tim Connect. Costandino, who was my supervisor and line manager back then, he did his best to get rid of me, but he
- 2:32
- Dorian Haci: couldn't. And so he I told him, well, we need to start a company together. And yeah, then that's how Midnero was born.
- 2:39
- Adam Fraser: Great. And I guess with your scientific background, electrical engineering, material science, could have gone in a number of directions in the processor chip space. What drew you to kind of the human body and ultimately the brain being the focus?
- 2:55
- Dorian Haci: Yeah, good question. So besides the fact that as I mentioned, there was the passion and the the research group working on that is really the possibility of using technology for good or using technology to create impact in the real world and to people that are suffering from medical conditions, in this case mostly from neurological conditions. And that really
- 3:15
- Dorian Haci: pushed us into coming out of academia, trying to find solutions that could become real in the real world, and then to start a company. Really the research was always at the intersection of the brain and electronics, and how we can use electronics to interact with the brain and to create solutions.
- 3:34
- Adam Fraser: We'll get into it when we talk about your funding, but as part of the work you've done over many, many years, there's been grant funding for many incredible research projects. And I think around twenty twenty two is when you took the plunge, you spun out of the lab into a a real life startup. What was that tipping point where you and your co founders said, right, this is kind of
- 3:54
- Adam Fraser: ready for prime time, or we're just ready to take this to the commercial world?
- 3:58
- Dorian Haci: It's never really a tipping point. It's a journey. It's a long journey. So I started studying electronics and doing a PhD by knowing that I really never wanted to become an academic. I loved academia. Most of my life was in academia, but I really wanted to take the technology and create solutions beyond writing research papers. And during that journey, then we
- 4:18
- Dorian Haci: really realized about some of the bottlenecks of the industry that we're we working in. So of technologies. Initially, most of the work that we did in academia is on electronics. for implantable medical devices. And what we really realized is that there was a bit of waste of time and technology because we were always reinventing the wheel, we're always developing more and more
- 4:38
- Dorian Haci: chips. We've designed over 40 chips in the past 15 years, specifically in NeuroTech. And then that a realization of we need a better technology, we need a better standard for foundational layer for chips and for electronics was what brought us to create a company that could actually work with the industry
- 4:58
- Dorian Haci: and provide to the industry the the best technology that we could build so that others could build the applications on top of that. For example, medical applications in epilepsy, we started from epilepsy, but as well as depression, we work with Motif, which is a company in the US that works in treatment of serial depression, as well as Parkinson's and other
- 5:18
- Dorian Haci: conditions. But it was really the realization of a hardware bottleneck that we, with our expertise, knowledge and technologies that we've developed in the past could address.
- 5:28
- Unidentified speaker (UNKNOWN): Look,
- 5:28
- Adam Fraser: great background, Doreen. Let's get into Mint Neuro. One of the things I'll talk about in this part I have some, like yourself, absolutely brilliant academic and scientific minds on the podcast. And I want to sort of dip into the scientific and engineering and material science, electronics in your case, level, but very much conscious it is a business podcast with business list,
- 5:48
- Adam Fraser: yeah, humble
- 5:49
- Unidentified speaker (UNKNOWN): CFOs
- 5:50
- Adam Fraser: like myself. But I think it is important we dip a little bit into what you're building. You know, with the AI revolution, everyone's suddenly an expert on NVIDIA and the difference between a GPU and a CPU, but we hear terms semiconductor. semiconductors, silicon, chips, processors, GPUs. Often these terms are used interchangeably. Just take us
- 6:10
- Adam Fraser: into the world of what you've built and give us some grounding in those kind of industry definitions and the sector you're playing in.
- 6:16
- Dorian Haci: And I'll try to keep it short because I never actually get too much to talk about the technical aspects, what I studied many years ago now as a CEO, but when I have had the opportunity I w I w want to say a few words. Anyway, so starting from semiconductor semiconductors, semiconductors are a class of materials that are not a conductor but that can become a conductor. So can you can control the the current flow into
- 6:36
- Dorian Haci: into these materials. And the most famous and used one in electronics is silicon, which is a material that can be made is actually called doping. You make the material conductive by injecting other type types of materials in it. And then over 50, 60 years ago, then people started using that to create the first electronic circuits. So the
- 6:56
- Dorian Haci: integrated circuits, the transistors. These transistors are the switches you can turn then on and off, but you can put billions of these transistors now, even trillions, in one single chip, as Nvidia has been doing. And when it really started, it was a lot about computing, and it's still a lot about computing, meaning that you take these transistors. that are zeros and
- 7:16
- Dorian Haci: ones, and you try to create digital circuits to make very complex calculations, like what's happening today with AI and with GPUs, CPUs. However, where we sit as Mint Neuro within this ecosystem is that we don't develop the typical circuits, CPUs that are doing these complex calculations or GPUs that are
- 7:35
- Dorian Haci: doing a ton of very simple calculations together in parallel. we sit at the intersection between the physical world and the digital world. Similar to technologies, for example, like microphones or cameras, or even like now with robotics to interact with the real world, you need electronics that can translate that real world signal into
- 7:55
- Dorian Haci: digital signal. And that's where our expertise comes, translating the biological signal, so the neural activity into the digital world and vice versa, taking commands from the digital world and generating signals to stimulate and modulate the nervous system to create treatments and therapies. And so these are called mixed signal
- 8:15
- Dorian Haci: circuits, and they're very different compared to GPUs, CPUs, and all that, because GPU, CPUs is more about, as I mentioned, calculation, computing, complexity from a math perspective. Whereas we are more about making the devices small enough to interact with the biology, um low power enough to last in the body for a long
- 8:35
- Dorian Haci: time, and also safe enough to be within the body without creating a problem to people who have these implants inside or outside of their body.
- 8:44
- Adam Fraser: Great. Thank you for the primer, Darian. Dorian. It's genuinely very helpful and I'm sure it is for our our listeners as well. So let's go into
- 8:51
- Adam Fraser: with that context what Mint Neuro have built, specifically focused on NeuroTech. I should say not just BCI. We will get into BCI, but many other devices, implants as well. I've seen some of your media and keynotes where you talk about, I guess, wanting to be the NVIDIA of the Neurotech sector. There's other analogies with
- 9:11
- Adam Fraser: Intel inside or with the iPhone and ARM design. designing the chip. There's different kinds of framing for this. But yeah, talk a bit about what you are building and have built inside of Mint Neuro.
- 9:22
- Dorian Haci: I mean, those three that you mentioned are are really our inspiration. Intel with Intel Inside really showed that you could bring computers on a desk. You can have personal computers. Our ARM created these very low power architectures that allowed computers to go into the phone, into our pockets. And now Nvidia, initially with gaming, then with cloud computing,
- 9:42
- Dorian Haci: and now with AI, showed that if you build a horizontal foundational layer from a chip perspective, then it's much easier to build applications on top of it because people don't need to reinvent the wheel. And that's really the assumption that we started. We believe that Neurotech has been reinventing the chip every time that the company comes out, but we
- 10:01
- Dorian Haci: believe that there should be a standard layer. And so what we have done is that we have created an architecture that can allow for that standardization of this field, which is very different from NVIDIA and others. We have created something which is more modular. And what we're really developing is what we call function specific chips instead of
- 10:21
- Dorian Haci: application application-specific specific chips. You might have heard in this industry people using the term ASICs, which is application. application-specific integrated circuit. But that means that the chip is optimized and developed for a specific application. For example, monitoring neural activity for epilepsy or stimulating the brain for treatment of Parkinson's. And
- 10:42
- Dorian Haci: that technology can't be used across other applications. And often these companies keep the IP, keep the technology for them because they need to win in the specific.
- 10:51
- Dorian Haci: vertical. What we have done is created this modular platform of multiple chips. I tend to think of it as Lego bricks. So instead of building a shape from scratch, then what we're building is we're building the bricks and the blocks. And then each of them is function-specific. For example, a function is to sense neural activity, to
- 11:11
- Dorian Haci: stimulate the brain, to create, for example, to do a processing. specific type of processing that is more for neurosignal processing, or safety features that are very important for implantable and wearable devices and connect with the neural system. And building this library of chips allows us then to have a starting point, to have the Lego bricks, and then
- 11:31
- Dorian Haci: combining them together with semiconductor technologies that now are becoming more and more used and also cheaper to have access to. then you can achieve that application specific system of chips rather than one chip doing that. And then the reuse of that IP and those blocks is what makes it applicable to a variety of
- 11:51
- Dorian Haci: conditions and applications.
- 11:53
- Adam Fraser: Very interesting. We'll get into business models down the track in terms of your go go-to-market. to market. And you mentioned your partnership with Matif Motif,
- 12:00
- Unidentified speaker (UNKNOWN): so
- 12:00
- Adam Fraser: you're very much in market already. The way you do describe that, you would very much partner with cus this isn't a kind of widget you sell off the shelf. Maybe one day in 30 years' time it becomes that commoditized, but you would work very closely with the development teams of your partner customers. Is that how you see your model evolving like a relatively
- 12:20
- Adam Fraser: non-number Number of customers, but very deep relationships with the ones you have?
- 12:25
- Dorian Haci: Absolutely. And that's that the the right word is really partner, partnerships. And the same thing that and others have done is owning a specific layer and work with people closely, with other companies closely to help them in their application. But just to say what's what's available out there today, right? So if you are a medical device company, BCI company, neurotech company, if you want chips,
- 12:45
- Dorian Haci: there's primarily three ways to get chips. The first one is you buy off the shelf. You can buy chips from catalog. catalogs. There's Texas Instrument, Analog devices, and all these big companies provide that create these chips. But these are often developed for other applications. It could be like from automotive or from telecommunication, right? And what you do in benchdop when you're starting to test your or
- 13:05
- Dorian Haci: your discovery phase from a scientific perspective, you build these chips on a printed circuit board on a PCB, and you try to see whether that can be applicable towards a specific method. medical condition or application. And then those chips are cheap, they're quick to get, but they are not optimised for the application and they're importantly not safe to be used in the human
- 13:25
- Dorian Haci: body. And so what then tends to happen is that is used as a primary test in bench top or first in human, just to show there's an application that that or like a discovery from a scientific perspective to create a treatment, for example. But then what happens is the second opportunity is once you get into human studies, then you need something which is a lot more
- 13:45
- Dorian Haci: specialized, a lot less power, a lot more miniaturized than what all the shelf components can provide. And that doesn't really exist today as of the shelf. So what tends to happen is the company has two directions. They either go to something called design houses. So these are specific semiconductor companies that do chip design. great technology. They're
- 14:05
- Dorian Haci: also optimized and specialized, but it takes two to three years and a few million to actually develop a chip. And often these companies that are developing a device, they don't have the luxury of waiting for years and spending millions into developing a new chip from scratch. And then the the last way is which
- 14:25
- Dorian Haci: a lot of DCI BCI companies, new near tech companies. are doing, is building their own team in-house to develop the chips. But often happens that people realize a lot a bit later that how difficult it is to build a semiconductor team, to have that expertise of that mixed signal skills that I mentioned earlier, and to create a team that can really deliver in a short amount of time
- 14:45
- Dorian Haci: a device that is specialized. And so there's nothing really that is off the shelf that can be used in human in a safe way and that you don't need to wait for many years to be available. And that's really where we fit in this industry. So we're creating these platform technologies, an ecosystem. And by doing that, we start
- 15:04
- Dorian Haci: collaborating very early on when they are developing in the lab, through the first in human studies, through the early feasibility studies, pyramidal studies, then approval for the market and even post market. So having a partnership that can support with the same technology throughout the journey is something that is currently missing.
- 15:24
- Unidentified speaker (UNKNOWN): Thanks
- 15:24
- Adam Fraser: Dorian. That's a great backdrop in terms of your backstory, what Mint Neuros building, the microprocessor the semiconductor industry more broadly. Let's get into BCI. I mean I know your tech is not just BCI. You have a partnership with Amber Therapeutics, for example, and there's other neuromodulation and DBS. I'm sure you want to play in a number of fields,
- 15:44
- Adam Fraser: but BCI is kind of a hot topic in Eurotech at the moment. There is a ton
- 15:48
- Unidentified speaker (UNKNOWN): of
- 15:48
- Adam Fraser: capital coming in. You've got the Elon Musk Neurolink PR effect. So just ease into it. I guess talk about your observations on how that sector has developed in the last decade. And also, I guess, in some ways, the horse has bolted with some of the players. Neuralink paradromics have been around since 2015, 2016, presumably
- 16:09
- Adam Fraser: have in-house development and solutions to the area you're now building in. So, yeah, talk a bit about what you observe at the BCI landscape.
- 16:16
- Dorian Haci: It's also important sometimes also to give some definitions because there's It's so many different definitions of the BCI term nowadays. But when I when I first joined this industry over 12 years ago now, I was really fascinated about neural interfaces they were called back then. So brain computer interfaces, brain machine interfaces as well. And then the whole field that has now
- 16:36
- Dorian Haci: evolved. But we, as more a horizontal approach, we have tried to define the whole field of neural devices and neural implants as well into different categories. And BCI, actually BCI corresponds to two different categories. One is what we call therapeutic. BCI. For example, Motif Neurotech is developing a therapeutic brain computer
- 16:55
- Dorian Haci: interface that interacts with the brain, but is to create a therapy. Then there's the what we call the enabling or motor BCI. So BCI is brain computer interfaces that connect with a part of the brain that is called motor cortex to measure activity of the brain to then control something externally, a robotic arm. a wheelchair,
- 17:15
- Dorian Haci: or a cursor on the screen. And so the activity in the part of the brain is still active, for example, for patients that have had a spinal cold injury. The activity is there in the brain to move, for example, the arm, but the signal is not traveling through the body to get to the arm. So if you can measure that activity there, then you can control the external devices. And then besides the
- 17:35
- Dorian Haci: BCIs, there's what we call neuromodulation, which is the more established industry. of creating treatment for Parkinson's, epilepsy, and so on, with big incumbents and players in the field. Then there's something that also the past few years have been quite hot in this field, which is bioelectronic medicine. About 10 years ago, it used to be called electroceuticals, but then it rebranded a bit. But it's
- 17:55
- Dorian Haci: really to address the nervous system, not primarily for neurological conditions, but to use the nervous system as a guidance. gateway to different organs within the body to, for example, treat inflammatory conditions or autoimmune conditions or even diabetes. And so these types of technologies interact with most of the peripheral nervous system
- 18:15
- Dorian Haci: for this type of application, even in urology. You mentioned amber therapeutics that we work with, they're creating a treatment for mixed urinary incontinence by interacting with the peripheral nervous nervous system. And of course I think the OGs of neural implants, the cochlear implants, which is part of the neuroprosthesis applications. So for example,
- 18:35
- Dorian Haci: devices that connect with the cochlea for sound or the retinal prosthesis and so on. So these five categories are what we believe is the neural implant world or neural device world at the moment. And NBCI BCI is the category that takes most of the noise, let's say. also because it has the opportunity, and that's also the noise comes from the
- 18:55
- Dorian Haci: investment that goes into this field and from some prominent entrepreneurs jumping in the field, is the opportunity to go beyond medical, going to something which is enhancement rather than medical. So once you have you can record signals from the brain and you can then interface with the external world and control lights turn on and off, then there's a
- 19:15
- Dorian Haci: huge world that opens in front of you. And so a lot of these companies, you mentioned a few, like Neuralink, Precision, Aerodromics, BlackRock NeuroTech, which has been around for a long time as well, and many others, they are focusing on those aspects. But at the end of the day, I believe that often it has to come to a medical
- 19:35
- Dorian Haci: intervention, has to come to showing how these technologies can. create impact, whether directly through a treatment or indirectly through allowing, for example, patients that are paralyzed to connect with the world and to also go back to work and so on. So different type of impact. But it has always to be, in my opinion, an impact to
- 19:54
- Dorian Haci: society through helping people that are suffering from conditions. And that also brings a bit more the healthcare economics aspects of this, because you're developing a device that needs then to go if it's implantable, because we're speaking more about implantable now, but if it goes to a patient, if it goes inside the body, you need to go through regulatory approval. After you have gone through
- 20:14
- Dorian Haci: that mountain, then there's the reimbursement mountain that you have to go through as well. And so you need to make sure that whatever you're developing can be paid. And in that you need to show that the impact that is creating that your device is creating, is also economically feasible and has to stay within the healthcare economics.
- 20:33
- Adam Fraser: So let's unpack what's happening in BCI a little bit and very pertinent to your business model and what you're building. I've said a couple of times on the pod, it's funny, I Dorian, I start this podcast in April, I used to say oh there's yeah, ten to twelve 12 credible, well funded BCI companies. I'd probably yeah, we're the fifteen to twenty, if not more, if you go globally, a lot of
- 20:52
- Adam Fraser: capital has come in. And again, to the headline reader, there's 20 companies say doing the same thing and competing for the same indications and use cases. Of course, when you dig deeper, there's some very different material science, there's some very different invasiveness, there's obviously different end focus And points. But what's fascinating to me and pertinent to
- 21:12
- Adam Fraser: you already, it's still a relatively new industry. the kind of supply chain being segmented. So you've got Neurosoft doing a deal with Science Corp. They feel they can play perhaps at the device material science level. Science Corp. provide the I'd call it the electronics platform for want of a nothing simple in this world, just to simplify how
- 21:32
- Adam Fraser: it's breaking down. I guess you're envisaging a world where people aren't necessarily competing on the chip. You envisage a world where you'd like to be the gold standard of processing unit, but then I guess people naturally compete in other areas, whether it's form factor, material science, invasiveness, electrodes, model,
- 21:51
- Adam Fraser: hardware, frankly, FDA clearance is evidence. So I guess how do you see this kind of BCI supply chain playing out, especially in a world where you're as successful as you'd like to be? How are people competing and differentiating?
- 22:05
- Unidentified speaker (speaker_2): There's a lot to unpack in there. I think I'll start with an anecdote. When I first started my PhD, some friends from uni started
- 22:12
- Dorian Haci: machine learning and deep learning. This was like 13 years ago. And I remember they were saying, Oh, there's there's this huge field of artificial intelligence that is coming and it will be huge. It will be like thousands of companies. I'm like, what what do you mean? Like Back then I was like, guys. you're in the wrong field. And of course I was wrong back then. But now I think I checked
- 22:32
- Dorian Haci: recently. There were like over 100,000 AI companies in the world. And then 10 years ago, no one would have thought that. I believe that Near Tech and BCI is where AI was 10 years ago. Where at that moment of a tipping point, a value inflection point for the whole industry. And you you've have had also your podcast, Chay. from Carter Sciences, that he
- 22:52
- Dorian Haci: is doing a great job in building this map of the whole world in Neurotech. And we've done our own job as well internally. And I think we've come to like one thousand eight hundred companies working in Neurotech in the world. Of course not all implantable. And we believe that it's not that they're going to be just two or three companies that are going to succeed. Multiple of these are going to succeed. Some are going to be even bigger than what the big ones are.
- 23:12
- Dorian Haci: And so what we want to be is that we want to make it simple for these companies to develop applications, to develop different types of applications, both in the medical realm, but also in the future outside of the medical, also in consumer markets, and that allows these companies to interact with the nervous system in a more direct and more precise way.
- 23:32
- Dorian Haci: And we believe that if there's a foundational layer like what Nvidia has done for AI, then you can actually build on top of it much easily and very importantly faster. And so that's how I see this industry growing. Once in our case, we're focusing on semiconductors, others are focusing on materials of electrodes, others are focusing on packaging and so on. We're
- 23:52
- Dorian Haci: focusing on one bottleneck, which we believe and history has told us is also right, E is one of the most important bottlenecks that once it's addressed, then speed of development of the whole industry goes really, really fast. So yeah, that that that's how I see it. But also importantly, I don't think that eight billion people will have an implantable device in the brain
- 24:12
- Dorian Haci: anytime soon. And I have quite a quite a strong opinion about implantables and wearables and especially invasive, invasive, non-invasive. I don't think there's invasive and or non-invasive. It's not like something which is a discrete or kind of like a duality. There's a level of invasiveness. Sometimes when you have a helmet, which is two kilos on your head, that's
- 24:32
- Dorian Haci: obtrusive. And so sometimes that is a lot more invasive than a device that sits on the chest is, for example, cardiac pacemakers that have been around for over 50 years. And so the level of invasiveness is is often very relative. And so I believe though that we'll get to a point in which implantable technologies will be
- 24:51
- Dorian Haci: a lot less invasive as it's defined today than many other technologies. And that will allow them to have multiple applications and to see the the scale of the industry. And that those devices need to be very low power, very miniaturized and very safe. And that's really what we focus on from a technical perspective.
- 25:11
- Unidentified speaker (UNKNOWN): So
- 25:11
- Adam Fraser: the analogy is not perfect, but increasingly large language models becoming commoditized. They're all get better and better. There's open source. People move up to the application layer. You see a kind of similar thing with Neurotech that the kind of core processing unit chips is not where people are competing, but it's the applications,
- 25:31
- Adam Fraser: in our case, the data, the use cases, then than the regulatory real-world real world friction as well. That's where people will compete ultimately in NeuroTech. and BCI.
- 25:40
- Unidentified speaker (speaker_2): Yeah, absolutely. Absolutely. And I think it's a journey. So I think sooner or later we'll have a Chat GPT moment also for NeuroTech. And that really will show that these type of devices can become more used and can actually create value because at the end of the day it's the value that someone's someone is creating. And at the application layer then that then you create you can create
- 25:59
- Unidentified speaker (speaker_2): significant value. And in our case we are like Nvidia bet on AI long before AI was a thing, because they were investing in early labs that were using these gaming chips to do parallel computing on this new statistic thing that was called machine learning and deep learning back then. And now now it's is the biggest thing in
- 26:19
- Unidentified speaker (speaker_2): the world. But I think betting Chatting early on on some of the innovators of this field is what we are doing and what we believe will be then the unlock for the whole industry.
- 26:29
- Adam Fraser: Final part of the interview, I want to get to your funding journey and commercial model and go to Barkie. But last question on the macro sector, it kind of the hot topic. A lot of capital. So again, you mentioned Cheikh, also Naveen Rao was the fifth episode. Roughly at least more than 50% of all funding in Eurotech is coming into BCI alone.
- 26:49
- Adam Fraser: It's brilliant technology. with an amazing vision. It's indistinguishable from sci-fi, all of that, but it is a very long term bet when you actually roll forward. You think of the number of human beings today with actual devices in their brains. It's still a tiny number in the bigger scheme of things. So you are looking five, ten, fifteen, twenty
- 27:09
- Adam Fraser: years out for real scalable commercial traction, yet there's hundreds of millions of dollars coming into this yeah, precision just at a $250 million raise. Just for one example, the market is seeing something. Why do you think we're seeing this flow of capital into NeuroTech? How much is kind of the musk effect and how much is just the
- 27:28
- Adam Fraser: attractiveness of the market dynamics?
- 27:31
- Unidentified speaker (speaker_3): I think it's is a a group of factors.
- 27:34
- Unidentified speaker (speaker_2): So I think on one end is that investors are starting to learn more and more about the fact that if you invest in
- 27:39
- Dorian Haci: something that is deep
- 27:40
- Unidentified speaker (UNKNOWN): tech,
- 27:40
- Dorian Haci: as it's called today,
- 27:41
- Unidentified speaker (speaker_2): that has
- 27:42
- Dorian Haci: technical scientific strength
- 27:45
- Unidentified speaker (UNKNOWN): and
- 27:45
- Dorian Haci: hypothesis
- 27:46
- Unidentified speaker (speaker_2): that can
- 27:47
- Dorian Haci: potentially in the future change either very significantly
- 27:51
- Unidentified speaker (speaker_2): life for
- 27:52
- Unidentified speaker (UNKNOWN): a
- 27:52
- Unidentified speaker (speaker_2): set
- 27:53
- Dorian Haci: of of people that might be limited to such as in medical applications, or
- 27:57
- Unidentified speaker (UNKNOWN): a
- 27:58
- Dorian Haci: bit
- 27:58
- Unidentified speaker (UNKNOWN): the
- 27:59
- Dorian Haci: change the life
- 28:00
- Unidentified speaker (UNKNOWN): of many
- 28:00
- Dorian Haci: people, billions of people,
- 28:02
- Unidentified speaker (UNKNOWN): then
- 28:03
- Dorian Haci: it's something to invest into. And
- 28:05
- Unidentified speaker (UNKNOWN): I
- 28:05
- Unidentified speaker (speaker_2): think this
- 28:05
- Dorian Haci: field
- 28:06
- Unidentified speaker (speaker_2): has both opportunities because in the medical realm, you can develop technologies that can give back life to people who who are suffering from these conditions. And the other end, again, once that Chad GPT moment will will arrive for this industry is something that will change completely how we interact with technology, with each other and with the world.
- 28:26
- Unidentified speaker (speaker_2): So I think that excitement is what's pushing the investors. The other thing is somehow intrinsically, we all have a bit of
- 28:33
- Dorian Haci: fascination with the brain. We all want to know a bit more about how our brain works, that people are are more in the understanding of consciousness and other higher level meanings of the brain and the nervous system. So I think that fascination is moving some of the investors. And So then what Elon did. 10 years ago, which was when he jumped in,
- 28:53
- Dorian Haci: he said, we need to protect
- 28:55
- Unidentified speaker (UNKNOWN): the
- 28:55
- Dorian Haci: humanity from AI. So I'm building Neuralink for that. And everyone was like, what on earth are you talking about? And
- 29:00
- Unidentified speaker (speaker_2): then now, actually, when you hear all on the news, all the risks around AI, you're
- 29:05
- Unidentified speaker (UNKNOWN): like,
- 29:05
- Unidentified speaker (speaker_2): oh, maybe he was he was not wrong. And so there's that aspect of interacting with artificial intelligence. And there was a recent article about called phase lock, which was about how humans then need to interact with the technology when with AI. So there's multiple aspects of the interest of investors, but I think it's a very exciting space.
- 29:25
- Adam Fraser: That face lock piece was very thought provoking and deep. I will link that in the show notes in case people haven't seen it in terms of kind of the longer term relationship between the brain, AI, tech, and to your point, Dorian, I agree. like we've got multi-trillion parameter large language models. We kind of sucked all the juice out of the written word
- 29:45
- Adam Fraser: and the kind of cumulative knowledge of humans. We're almost there at superintelligence, but the brain remains so misunderstood. It feels like it's the next phase of this journey.
- 29:56
- Dorian Haci: And it's very difficult because we are in that space of translating, as I mentioned from biology digital world, but for example with language and with images, you have the token, you have the discrete element that you can then use to train kind of like a large language model or generative AI. In neuroscience, it's very
- 30:16
- Dorian Haci: difficult to understand which part of like is it like the action potential? What is the element, And the token? But whatever it is, whatever the whole community will decide in the future, you need precision. in measuring that signal. And that it comes to the ability to translate well the signal, the biological signal to the digital world. And that's that's where
- 30:36
- Dorian Haci: a lot of bottleneck still is today.
- 30:39
- Adam Fraser: Yeah. We talk often at omniscient with the work we're doing with connectomics and brain mapping, the importance of precision, Vision, literally, millimeters and micromillimeters micro millimeters matter when you're targeting the brain for different interventions. So, Dorian, let's look, last part of Conscious of Time. I do want to get to your funding journey. So we're talking about the macro market and all the amazing things happening.
- 30:58
- Adam Fraser: Congratulations, you just raised a five million dollar round, I believe. I know you'd had some grant funding
- 31:04
- Adam Fraser: in advance of that. So yeah, just talk about the evolution of Mint Neuros funding since you began and the latest round and who you've brought in.
- 31:12
- Dorian Haci: So when we really started four years ago. now, we did our best to avoid raising investment immediately. We wanted really to have the transition from academia to a company and try to de-risk the technology further. And so we managed to secure significant amount of grant funding and to work then with partners and collaborators to build our
- 31:32
- Dorian Haci: IP and our in our first chip so that we can then test in the real world. And that really helped a lot. We were very lucky to obtain funding from the NIHR, Innovate UK, and then last year also from ARIA, which is the advanced research and invention agency in the UK. And that allowed to build partnerships and to de-risk the technology to a point where it is a
- 31:52
- Dorian Haci: prototype, it is a minimum viable product that can go into the market. And that's where we started uh raising. About two years ago we raised one 1 million pounds, which is 1.3 million dollars. And then a month ago, we closed the five million dollars. And so what we tried to do is to build a syndicate of investors that understood both the
- 32:12
- Dorian Haci: enabling technology, so the semiconductors, hardware aspects, as well as the application layer. So the medical realm and the neurology and so on. And that is tough because on in general, you want to go to one investor, get most of the money from one. investor, and then have others can help. But what we try to do is to bring together multiple investors that could
- 32:32
- Dorian Haci: help us beyond capital, could help us in opening doors, meet potential partners, team members, and so on. And that I think in the long term, also in the short term, has been a good choice. And we've brought our lead investor was Odyssey Ventures. They are AI and deep tech investor based in London. but they have offices also in
- 32:52
- Dorian Haci: San Francisco, New York. And their whole thesis is to help companies in Europe scale internationally. And so that really aligns with with our approach as well. And again, we have had a lot of investors that have helped us beyond capital and for the next phase of the company.
- 33:09
- Adam Fraser: I know very well during the life in a startup you finish one round and immediately start planning the next round because the patient needs constant oxygen. But yeah, five million, very commendable achievement, but in the scale of Neurotech funding, still a relatively small amount for the vision you've just described. How capital intensive do you see
- 33:29
- Adam Fraser: the next five years being? What's your broad kind of roadmap as you see it right now in terms of quantum and also location? Do you see like a US VC V C or more US based investors as important?
- 33:40
- Dorian Haci: Yeah, that's a very very good point. And I think if I were to summarize our approach in one word, we'll be resourceful. We've been very resourceful, not just in how we have approached building the company and growing the company, but also in how we see the industry going. I told you earlier that we believe there's there's a waste in terms of resources being used to redevelop the chip from
- 33:59
- Unidentified speaker (speaker_2): scratch. And I think we want to create a model that can use resources in a more efficient way. In the same way we have been also around the fundraising. So we've started well small, building the team, now we're almost thirty people in the company and growing step by step and and validating the next step up to then the point in which we have the technology in the market
- 34:20
- Unidentified speaker (speaker_2): and then we'll we'll have that in the day scalability. But I think we've been very cautious and resourceful and efficient in using the
- 34:27
- Dorian Haci: capital and the technology.
- 34:29
- Unidentified speaker (speaker_2): Of course, to become NVIDIA, you need to raise as much as NVIDIA has have raised. But they started the same way. They started in 1993. Initially, they went into gaming, having having specific prototypes, and growing from there, from having something in the market. And that's the same approach we want to do. In terms of how we grow as a company, of course, the UK is the biggest market,
- 34:49
- Unidentified speaker (speaker_2): although markets are growing very fast in other places in Asia as well. And
- 34:54
- Dorian Haci: we want really to be a global company. We want to enable the whole industry and the whole world to be able to build on top of our platform technology. And so definitely the US, now I'm in San Francisco. I will be spending time in the in the US in the future as well. And yeah, growing, becoming an int international company.
- 35:12
- Adam Fraser: Yeah. And video overnight success. after fifteen to twenty years of grind. People forget when you look at like the long-term share price chart from video, it's a long journey. When you see these success stories, often it's yeah, a lot of blood, sweat and tears to get there.
- 35:27
- Unidentified speaker (UNKNOWN): Yeah,
- 35:28
- Dorian Haci: and NVIDIA also actually when we started, I was checking when NVIDIA became then a billion dollar revenue company. And I was thinking like probably 2015, 2016 and so on. In 2002 they actually crossed the $1 billion revenue. So they've been slowly building their reputation in the field around specific technical capabilities.
- 35:48
- Dorian Haci: And that's the type of approach that we want to take as well. And also importantly, to work with partners, to work with people that are at the edge, that are developing innovative technologies that can create real products.
- 36:00
- Adam Fraser: Yeah. So final question, Dorian. We touched on one of your founders, but in looking at your founder story, multiple decades of deep scientific, you know, electrical engineering, material science expertise, deep, deep scientific capability. You're now in the commercial world, you're like the nominated driver of the four of you. You are kind of the
- 36:20
- Adam Fraser: most commercial one. But in all seriousness, how have you found that transition from the lab into the market? You're dealing with the wall. wolves of Wall Street, you're having to talk Silicon Valley lingo. How are you finding that journey yourself?
- 36:32
- Dorian Haci: It's a very, very difficult journey, of course, but it's a journey that I would I would do a hundred times. And I was very lucky in my in my life to meet the right people at the right time. People tell me
- 36:43
- Unidentified speaker (speaker_2): that when I say that I have 12 years in the industry, they're like, oh wow. I'm like, no, I'm actually the black sheep of the founding team. Oh
- 36:49
- Unidentified speaker (UNKNOWN): Tim
- 36:49
- Unidentified speaker (speaker_2): Cosandino, Tim Dennison, Denison, Andy James. Jackson, they all have 20, 25 years experience in the field coming from Tim Cosandino from semiconductors, Tim Denison from medical devices for over 15 years at Medtronic, Andy Jackson, BCI or neuroscience, brain and mind in the field. So I've been lucky to have people around me that been my mentors as well.
- 37:09
- Unidentified speaker (speaker_2): And then I
- 37:10
- Dorian Haci: always had the ambition to build a company that can create real impact in the world. But I really wanted to have the deep knowledge and understanding of the field that I was working in. That's why I did an academic career before. And then transitioning then to becoming the CEO and the and the main catalyst of the company in the next phase has always been something that I wanted to do. It hasn't
- 37:30
- Dorian Haci: been easy because I realized afterwards that all those technical capabilities of designing chips myself and so on, I can't really use today. Because
- 37:38
- Adam Fraser: yeah.
- 37:38
- Dorian Haci: I mean, thankfully I can't use them because there are people that can develop chips much better than what I did. But having that knowledge of the technical aspects allows me to understand what the limitations are with technology and how we adapt that technology and to work with people who are the best in the world at doing that. From a business perspective and commercial perspective,
- 37:58
- Dorian Haci: when I was transitioning from my academic career to starting a company, I did a lot of training. I was lucky to be part of something called MatEx Superconnector. I became an enterprise fellow of the Royal Academy of Engineering. I was part of Chipstart UK. So there were a lot of these programs that trained me in the business world. And I think business aspects can be learned.
- 38:19
- Dorian Haci: And now though, as we're scaling as a company, of course, we're gonna grow more on the product and on the commercial aspects and build building a team that can deal both with uh investors with getting that funding and also with the partners and customers to make what we have real products.
- 38:35
- Adam Fraser: Welcome to our side of the fence. We have our own acronym universe, yeah, IRR, MPV, ROIC. Because I'm constantly being bamboozled by my brilliant scientific colleagues with their acronyms. We we do have our own acronyms too, but it sounds like you've very much adapted to
- 38:50
- Unidentified speaker (UNKNOWN): I'm
- 38:50
- Dorian Haci: learning.
- 38:51
- Adam Fraser: the commercial world as well. Look, Dorian, I could talk for hours, but I want to be respectful of your time. Thank you so, so much for joining the Business of NeuroTech podcast. Congratulations on the progress today, the brilliant work you and your founder team are doing. I work in the field day in, day out. I share your passion and belief for where this sector can go over the next kind of five, ten,
- 39:10
- Adam Fraser: fifteen years. The fact that kind of foundational picks and shovels provide providers like yourself are now emerging, I think is a sign we're we're making progress. The sector is maturing. So I look forward to following your future successes. Before I let you go, where do you want to send people, Dorian, that may want to follow what you're writing about online and learn more about the work
- 39:30
- Adam Fraser: Mint Neuro are doing?
- 39:32
- Dorian Haci: Yes. So our website Mintneuro.com and I'm quite active also on LinkedIn and post about my thoughts on the industry and and where where we're going next. So you can find me there.
- 39:44
- Unidentified speaker (UNKNOWN): I
- 39:44
- Adam Fraser: will add that to the show notes. Dorian, thank you so so much for joining the show.
- 39:47
- Unidentified speaker (UNKNOWN): Thank
- 39:47
- Dorian Haci: you, Adam. It was an absolute pleasure, and I'm looking forward to your next episodes.
- 39:53
- Adam Fraser: Thanks for listening to the show. For more information on the podcast, individual show notes, and all the links about where you can find the show, please visit business.com. businessofneurotech.com. We look forward to seeing you on a future episode.